Literature DB >> 21767717

Productivity savings from colorectal cancer prevention and control strategies.

Cathy J Bradley1, Iris Lansdorp-Vogelaar, K Robin Yabroff, Bassam Dahman, Angela Mariotto, Eric J Feuer, Martin L Brown.   

Abstract

BACKGROUND: Lost productivity represents a considerable portion of the total economic burden of colorectal cancer (CRC), but cost-effectiveness studies of CRC prevention and control have not included these costs and therefore underestimate potential savings from CRC prevention and control.
PURPOSE: To use microsimulation modeling study to estimate and project productivity costs of CRC and to model the savings from four approaches to reducing CRC incidence and mortality: risk factor reduction, improved screening, improved treatment, and a simultaneous approach where all three strategies are implemented.
METHODS: A model was developed to project productivity losses from CRC using the U.S. population with CRC incidence and mortality projected through the year 2020. Outcome measures were CRC mortality, morbidity, and productivity savings.
RESULTS: With 2005 levels in risk factors, screening, and treatment, 48,748 CRC deaths occurred in 2010, amounting to $21 billion of lost productivity. Using prevention and treatment strategies simultaneously, 3586 deaths could have been avoided in 2010, leading to a savings of $1.4 billion. Cumulatively, by 2020, simultaneous strategies that reduce risk factors and increase screening and treatment could result in 101,353 deaths avoided and $33.9 billion in savings in reduced productivity loss. Improved screening rates alone led to nearly $14.7 billion in savings between 2005 and 2020, followed by risk factor reduction ($12.4 billion) and improved treatment ($8.4 billion).
CONCLUSIONS: The savings in productivity loss from strategies to reduce CRC incidence and mortality are substantial, providing evidence that CRC prevention and control strategies are likely to be cost-saving.
Copyright © 2011 American Journal of Preventive Medicine. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21767717      PMCID: PMC3139918          DOI: 10.1016/j.amepre.2011.04.008

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  33 in total

Review 1.  Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force.

Authors:  Michael Pignone; Somnath Saha; Tom Hoerger; Jeanne Mandelblatt
Journal:  Ann Intern Med       Date:  2002-07-16       Impact factor: 25.391

2.  Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.

Authors:  Anna E Coghill; Polly A Newcomb; Peter T Campbell; Andrea N Burnett-Hartman; Scott V Adams; Elizabeth M Poole; John D Potter; Cornelia M Ulrich
Journal:  Gut       Date:  2010-11-04       Impact factor: 23.059

3.  Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey.

Authors:  Judith Swan; Nancy Breen; Ralph J Coates; Barbara K Rimer; Nancy C Lee
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

4.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

5.  Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer.

Authors:  Arnold L Potosky; Linda C Harlan; Richard S Kaplan; Karen A Johnson; Charles F Lynch
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  The prevalence of patients with colorectal carcinoma under care in the U.S.

Authors:  Angela Mariotto; Joan L Warren; Kevin B Knopf; Eric J Feuer
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

7.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies.

Authors:  Eunyoung Cho; Stephanie A Smith-Warner; John Ritz; Piet A van den Brandt; Graham A Colditz; Aaron R Folsom; Jo L Freudenheim; Edward Giovannucci; R Alexandra Goldbohm; Saxon Graham; Lars Holmberg; Dong-Hyun Kim; Nea Malila; Anthony B Miller; Pirjo Pietinen; Thomas E Rohan; Thomas A Sellers; Frank E Speizer; Walter C Willett; Alicja Wolk; David J Hunter
Journal:  Ann Intern Med       Date:  2004-04-20       Impact factor: 25.391

10.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

View more
  15 in total

1.  Patient activation increases colorectal cancer screening rates: a randomized trial among low-income minority patients.

Authors:  Mira L Katz; James L Fisher; Kelly Fleming; Electra D Paskett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-11-08       Impact factor: 4.254

2.  Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities.

Authors:  K Robin Yabroff; Silvia Francisci; Angela Mariotto; Maura Mezzetti; Anna Gigli; Joseph Lipscomb
Journal:  J Natl Cancer Inst Monogr       Date:  2013

3.  Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective.

Authors:  Chunyu Li; Steven B Zeliadt; Ingrid J Hall; Judith Lee Smith; Donatus U Ekwueme; Carol M Moinpour; David F Penson; Ian M Thompson; Thomas E Keane; Scott D Ramsey
Journal:  Support Care Cancer       Date:  2013-08-17       Impact factor: 3.603

Review 4.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

Review 5.  Economic studies in colorectal cancer: challenges in measuring and comparing costs.

Authors:  K Robin Yabroff; Laurel Borowski; Joseph Lipscomb
Journal:  J Natl Cancer Inst Monogr       Date:  2013

Review 6.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

7.  The impact of preventive screening resource distribution on geographic and population-based disparities in colorectal cancer in Mississippi.

Authors:  Fazlay S Faruque; Xu Zhang; Elizabeth N Nichols; Denae L Bradley; Royce Reeves-Darby; Vonda Reeves-Darby; Roy J Duhé
Journal:  BMC Res Notes       Date:  2015-09-08

Review 8.  The global impact of non-communicable diseases on macro-economic productivity: a systematic review.

Authors:  Layal Chaker; Abby Falla; Sven J van der Lee; Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-04-03       Impact factor: 8.082

9.  Risk Factors for Diagnosis of Colorectal Cancer at a Late Stage: a Population-Based Study.

Authors:  Angeline S Andrew; Siddhartha Parker; Joseph C Anderson; Judy R Rees; Christina Robinson; Bruce Riddle; Lynn F Butterly
Journal:  J Gen Intern Med       Date:  2018-10-03       Impact factor: 6.473

10.  Radiolabelled polymeric IgA: from biodistribution to a new molecular imaging tool in colorectal cancer lung metastases.

Authors:  Helene Carpenet; Armelle Cuvillier; Aurélie Perraud; Ophélie Martin; Gaël Champier; Marie-Odile Jauberteau; Jacques Monteil; Isabelle Quelven
Journal:  Oncotarget       Date:  2017-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.